e-learning
resources
Vienna 2003
Tuesday 30.09.2003
Cancer and complications
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
A cost minimisation comparison of five chemotherapy regimes for advanced nonsmall cell lung cancer
H. G. Bischoff, D. Tilden, A. Kielhorn, C. Heuser (Heidelberg, Bad Homburg, Germany; London, United Kingdom)
Source:
Annual Congress 2003 - Cancer and complications
Session:
Cancer and complications
Session type:
Thematic Poster Session
Number:
2761
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. G. Bischoff, D. Tilden, A. Kielhorn, C. Heuser (Heidelberg, Bad Homburg, Germany; London, United Kingdom). A cost minimisation comparison of five chemotherapy regimes for advanced nonsmall cell lung cancer. Eur Respir J 2003; 22: Suppl. 45, 2761
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer
Source: Eur Respir J 2006; 27: 895-901
Year: 2006
Use of 2
nd
-line polychemotherapy in advanced nonsmall cell lung cancer – a reasonable approach
Source: Eur Respir J 2003; 22: Suppl. 45, 65s
Year: 2003
The method of individualisation of treatment and prognosis for advanced non-small cell lung cancer
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010
Radiotherapy in the treatment of nonsmall cell lung cancer
Source: Eur Respir Mon; 2009: 44: 207–243
Year: 2009
Combined radiotherapy for nonsmall cell lung cancer
Source: Eur Respir J 2003; 22: Suppl. 45, 31s
Year: 2003
Impact of radiotherapy on outcomes of nivolumab in advanced non-small cell lung cancer: a case controlled study
Source: International Congress 2018 – Lung cancer: personalised medicine
Year: 2018
Second-line therapy in elderly patients with advanced nonsmall cell lung cancer
Source: Eur Respir J 2014; 43: 240-249
Year: 2004
First- and second-line therapy for advanced nonsmall cell lung cancer
Source: Eur Respir J 2009; 33: 915-930
Year: 2009
Chemotherapy in advanced nonsmall cell lung cancer
Source: Eur Respir Mon; 2009: 44: 271–283
Year: 2009
Comparison of quality of life in patients with non-small cell lung cancer treated by chemotherapy or radiotherapy
Source: Eur Respir J 2004; 24: Suppl. 48, 75s
Year: 2004
Second line therapy for advanced non-small cell lung cancer
Source: European Multidisciplinary Conference in Thoracic Oncology 2009
Year: 2009
Lung function evaluation in gemcitabine and concurrent radiotherapy treatment in nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2001; 18: Suppl. 33, 376s
Year: 2001
Treatment of advanced non-small cell lung cancer
Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment
Year: 2005
Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer
Source: ERJ Open Res, 4 (2) 00120-2017; 10.1183/23120541.00120-2017
Year: 2018
Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives
Source: Eur Respir Rev 2011; 20: 45-52
Year: 2011
Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy?
Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies
Year: 2007
Correlation between parameters of quality of life in patients with non-small cell lung cancer treated by chemotherapy and radiotherapy
Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology
Year: 2007
Impact of neoadjuvant therapy on tumor resectability and survival of patients with locally advanced non-small cell lung cancer
Source: Annual Congress 2011 - General thoracic surgery II
Year: 2011
Radio(chemo)therapy in locally advanced nonsmall cell lung cancer
Source: Eur Respir Rev 2015; 25: 65-70
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept